Traws Pharma, Inc.
TRAWDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How TRAW's past catalysts played out
ON 01910.Na
Myelodysplastic Syndrome
rigosertib sodium
Myelodysplastic Syndromes
rigosertib
Head and Neck Squamous Cell Carcinoma
Oral rigosertib
Myelodysplastic Syndromes
TRX-100
Influenza
Narazaciclib
Endometrioid Endometrial Cancer
Ratutrelvir (83-0060) non-randomised
COVID - 19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ON 01910.Na | Phase 3 | Myelodysplastic Syndrome | - | - |
rigosertib sodium | Phase 3 | Myelodysplastic Syndromes | - | - |
rigosertib | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Oral rigosertib | Phase 2 | Myelodysplastic Syndromes | - | - |
TRX-100 | Phase 2 | Influenza | - | - |
Narazaciclib | Phase 2 | Endometrioid Endometrial Cancer | - | - |
Ratutrelvir (83-0060) non-randomised | Phase 2 | COVID - 19 | - | - |
Myelodysplastic Syndromes
2 drugs in this indication
Endometrioid Endometrial Cancer
1 drug in this indication
COVID - 19
1 drug in this indication
Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Myelodysplastic Syndrome
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Traws Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Traws Pharma, Inc.'s (TRAW) pipeline across Phase 3, Phase 2. Its lead program is ON 01910.Na (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Traws Pharma, Inc.'s next FDA catalyst?→
Traws Pharma, Inc.'s (TRAW) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRAW biotech catalysts?→
Add TRAW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Traws Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.